Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:18:03.554Z.
Consensus retrieved: 2026-10-06T16:04:19.483Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:18:03.554Z.
Quote observation: 2026-10-06T17:15:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 42b016fbc5a973102d15f7ad9d293c118a3bb0a9148463a489c94e3aff1da7c0
Forward PE Ratio (N/A) = Dated Quote Price ($90.33) / Consensus Forward EPS ($-2.98)
FORWARD PE RATIO
N/A
Rhythm Pharmaceuticals, Inc.
Market Cap
$6.20B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | $6.20B | N/A |
| GRAIL Inc. (GRAL)vs › | $6.03B | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.94B | 31.87 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.92B | N/A |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 19.86 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.50B | 18.45 |
| Immunovant, Inc. (IMVT)vs › | $6.52B | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.53B | N/A |
| Kodiak Sciences Inc. (KOD)vs › | $5.82B | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.75B | 54.13 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $90.33, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.98 | $-3.26 – $-2.65 | 10 | n/m |
| 2027-12-31 | $-0.70 | $-1.69 – $0.23 | 10 | n/m |
| 2028-12-31 | $2.34 | $0.26 – $4.17 | 10 | 38.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
